Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Retained Earnings: 2017-2025

Historic Retained Earnings for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$743.7 million.

  • Cidara Therapeutics' Retained Earnings fell 33.04% to -$743.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$743.7 million, marking a year-over-year decrease of 33.04%. This contributed to the annual value of -$611.3 million for FY2024, which is 38.47% down from last year.
  • As of Q3 2025, Cidara Therapeutics' Retained Earnings stood at -$743.7 million, which was down 12.60% from -$660.5 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Retained Earnings registered a high of -$342.3 million during Q2 2021, and its lowest value of -$743.7 million during Q3 2025.
  • Its 3-year average for Retained Earnings is -$538.9 million, with a median of -$543.0 million in 2024.
  • Data for Cidara Therapeutics' Retained Earnings shows a maximum YoY crashed of 40.50% (in 2025) over the last 5 years.
  • Cidara Therapeutics' Retained Earnings (Quarterly) stood at -$377.2 million in 2021, then declined by 10.96% to -$418.5 million in 2022, then declined by 5.48% to -$441.4 million in 2023, then plummeted by 38.47% to -$611.3 million in 2024, then crashed by 33.04% to -$743.7 million in 2025.
  • Its Retained Earnings stands at -$743.7 million for Q3 2025, versus -$660.5 million for Q2 2025 and -$634.7 million for Q1 2025.